22504 Seek, Find, and Treat: Best Practices for Managing Patients With Transthyretin Amyloid Polyneuropathy (ATTR-PN)

In this program, experts Drs. Morie Gertz, Michelle Mauermann, Sami Khella, and Ronald Witteles will describe best practices for the diagnosis, treatment, and monitoring of disease progression in these patients.

Transthyretin amyloidosis (ATTR) is a progressive disease characterized by the abnormal buildup of amyloid deposits composed of misfolded transthyretin protein in the body’s organs and tissues. Symptoms of ATTR amyloidosis are similar to those of other diseases, thus it can be difficult to recognize and diagnose. Since ATTR is fatal if untreated, early identification, diagnosis, and treatment are critical. ATTR is either hereditary or wild type. ATTR is named according to the location of the amyloid deposits – if in the nerves, it is referred to as ATTR-polyneuropathy (ATTR-PN). ATTR-PN can also involve buildup of TTR amyloid in the autonomic system, and patients can have both transthyretin amyloid cardiomyopathy (ATTR-CM) and ATTR-PN. In this program, experts Drs. Morie Gertz, Michelle Mauermann, Sami Khella, and Ronald Witteles will describe best practices for the diagnosis, treatment, and monitoring of disease progression in these patients.

Login to your Account